Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports

Analysis of the brain specific biomarkers amyloid β(42) (Aβ(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Slats, Diane, Spies, Petra E., Sjögren, Magnus J.C., Verhey, Frans R.J., Verbeek, Marcel M., Olde Rikkert, Marcel G.M.
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: February 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914365/
https://www.ncbi.nlm.nih.gov/pubmed/20689628
http://dx.doi.org/10.1159/000286280
_version_ 1782184755110871040
author Slats, Diane
Spies, Petra E.
Sjögren, Magnus J.C.
Verhey, Frans R.J.
Verbeek, Marcel M.
Olde Rikkert, Marcel G.M.
author_facet Slats, Diane
Spies, Petra E.
Sjögren, Magnus J.C.
Verhey, Frans R.J.
Verbeek, Marcel M.
Olde Rikkert, Marcel G.M.
author_sort Slats, Diane
collection PubMed
description Analysis of the brain specific biomarkers amyloid β(42) (Aβ(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.
format Text
id pubmed-2914365
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-29143652010-08-05 Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports Slats, Diane Spies, Petra E. Sjögren, Magnus J.C. Verhey, Frans R.J. Verbeek, Marcel M. Olde Rikkert, Marcel G.M. Case Rep Neurol Published: February 2010 Analysis of the brain specific biomarkers amyloid β(42) (Aβ(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD. S. Karger AG 2010-02-24 /pmc/articles/PMC2914365/ /pubmed/20689628 http://dx.doi.org/10.1159/000286280 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: February 2010
Slats, Diane
Spies, Petra E.
Sjögren, Magnus J.C.
Verhey, Frans R.J.
Verbeek, Marcel M.
Olde Rikkert, Marcel G.M.
Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
title Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
title_full Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
title_fullStr Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
title_full_unstemmed Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
title_short Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
title_sort cerebrospinal fluid biomarkers in diagnosing alzheimer's disease in clinical practice: an illustration with 3 case reports
topic Published: February 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914365/
https://www.ncbi.nlm.nih.gov/pubmed/20689628
http://dx.doi.org/10.1159/000286280
work_keys_str_mv AT slatsdiane cerebrospinalfluidbiomarkersindiagnosingalzheimersdiseaseinclinicalpracticeanillustrationwith3casereports
AT spiespetrae cerebrospinalfluidbiomarkersindiagnosingalzheimersdiseaseinclinicalpracticeanillustrationwith3casereports
AT sjogrenmagnusjc cerebrospinalfluidbiomarkersindiagnosingalzheimersdiseaseinclinicalpracticeanillustrationwith3casereports
AT verheyfransrj cerebrospinalfluidbiomarkersindiagnosingalzheimersdiseaseinclinicalpracticeanillustrationwith3casereports
AT verbeekmarcelm cerebrospinalfluidbiomarkersindiagnosingalzheimersdiseaseinclinicalpracticeanillustrationwith3casereports
AT olderikkertmarcelgm cerebrospinalfluidbiomarkersindiagnosingalzheimersdiseaseinclinicalpracticeanillustrationwith3casereports

Ejemplares similares